"Xoma would be the perfect candidate."http://money.cnn.com/2010/06/15/news/companies/sanofi_aventis_viehbacher.fortune/index.htm
$300,000,000 for Xoma.How could the B.O.D. turn down such an offer?
Orphan drug status of X052 is a major plus.
Takeda has to be considered the front runner.
Too cheap here.$100,000,000 in revenues over the next twelve months.
"GSK and SNY are on the prowl here."
The glass is more than half full.My cup runneth over sooner than later.
GSK needs to replace Avandia.